Valproic Acid Use During Radiation Therapy for Glioblastoma Associated with Improved Survival

Overview

Journal Int J Radiat Oncol Biol Phys

Specialties Oncology
Radiology

Date 2013 Mar 26

PMID 23523186

Citations 71

Authors

Christopher A Barker

Andrew J Bishop

Maria Chang

Kathryn Beal

Timothy A Chan

Affiliations

Soon will be listed here.

Abstract

Purpose: Valproic acid (VA) is an antiepileptic drug (AED) and histone deacetylase (HDAC) inhibitor taken by patients with glioblastoma (GB) to manage seizures, and it can modulate the biologic effects of radiation therapy (RT). We investigated whether VA use during RT for GB was associated with overall survival (OS).

Methods And Materials: Medical records of 544 adults with GB were retrospectively reviewed. Analyses were performed to determine the association of Radiation Therapy Oncology Group recursive partitioning analysis (RTOG RPA) class, seizure history, and concurrent temozolomide (TMZ) and AED use during RT with OS.

Results: Seizures before the end of RT were noted in 217 (40%) patients, and 403 (74%) were taking an AED during RT; 29 (7%) were taking VA. Median OS in patients taking VA was 16.9 months (vs 13.6 months taking another AED, P=.16). Among patients taking an AED during RT, OS was associated with VA (P=.047; hazard ratio [HR], 0.67; 95% confidence interval [CI], 0.27-1.07), and RTOG RPA class (P<.0001; HR, 1.49; 95% CI, 1.37-1.61). Of the 5 most common AEDs, only VA was associated with OS. Median OS of patients receiving VA and TMZ during RT was 23.9 months (vs 15.2 months for patients taking another AED, P=.26). When the analysis was restricted to patients who received concurrent TMZ, VA use was marginally associated with OS (P=.057; HR, 0.54; 95% CI, -0.09 to 1.17), independently of RTOG RPA class and seizure history.

Conclusions: VA use during RT for GB was associated with improved OS, independently of RTOG RPA, seizure history, and concurrent TMZ use. Further studies of treatment that combines HDAC inhibitors and RT are warranted.

Citing Articles

Levetiracetam and valproic acid in glioma: antiseizure and potential antineoplastic effects.

Khalili B, Walbert T, Horbinski C, Dixit K, Gururangan K, Thio H Future Oncol. 2025; 21(4):483-491.

PMID: 39786974 PMC: 11812422. DOI: 10.1080/14796694.2025.2450215.

Unexplained Causes of Glioma-Associated Epilepsies: A Review of Theories and an Area for Research.

Saviuk M, Sleptsova E, Redkin T, Turubanova V Cancers (Basel). 2023; 15(23).

PMID: 38067243 PMC: 10705208. DOI: 10.3390/cancers15235539.

Identifying patients suitable for targeted adjuvant therapy: advances in the field of developing biomarkers for tumor recurrence following irradiation.

Jagasia S, Tasci E, Zhuge Y, Camphausen K, Krauze A Expert Rev Precis Med Drug Dev. 2023; 8(1):33-42.

PMID: 37982134 PMC: 10655913. DOI: 10.1080/23808993.2023.2276927.

Brief report: pediatric high-grade gliomas treated with vinorelbine and valproic acid added to temozolomide.

Guidi M, Giunti L, Buccoliero A, Fonte C, Scoccianti S, Censullo M Am J Cancer Res. 2023; 13(8):3668-3678.

PMID: 37693163 PMC: 10492125.

HDAC1 and HDAC6 are essential for driving growth in IDH1 mutant glioma.

Garrett M, Albano R, Carnwath T, Elahi L, Behrmann C, Pemberton M Sci Rep. 2023; 13(1):12433.

PMID: 37528157 PMC: 10394035. DOI: 10.1038/s41598-023-33889-3.

References

Curran Jr W, Scott C, Horton J, Nelson J, Weinstein A, Fischbach A . Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst. 1993; 85(9):704-10. DOI: 10.1093/jnci/85.9.704. View

van Breemen M, Rijsman R, Taphoorn M, Walchenbach R, Zwinkels H, Vecht C . Efficacy of anti-epileptic drugs in patients with gliomas and seizures. J Neurol. 2009; 256(9):1519-26. DOI: 10.1007/s00415-009-5156-9. View

Ruben J, Dally M, Bailey M, Smith R, McLean C, Fedele P . Cerebral radiation necrosis: incidence, outcomes, and risk factors with emphasis on radiation parameters and chemotherapy. Int J Radiat Oncol Biol Phys. 2006; 65(2):499-508. DOI: 10.1016/j.ijrobp.2005.12.002. View

Glantz M, Cole B, Forsyth P, Recht L, Wen P, Chamberlain M . Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2000; 54(10):1886-93. DOI: 10.1212/wnl.54.10.1886. View

Oberndorfer S, Piribauer M, Marosi C, Lahrmann H, Hitzenberger P, Grisold W . P450 enzyme inducing and non-enzyme inducing antiepileptics in glioblastoma patients treated with standard chemotherapy. J Neurooncol. 2005; 72(3):255-60. DOI: 10.1007/s11060-004-2338-2. View

Chinnaiyan P, Cerna D, Burgan W, Beam K, Williams E, Camphausen K . Postradiation sensitization of the histone deacetylase inhibitor valproic acid. Clin Cancer Res. 2008; 14(17):5410-5. PMC: 3393085. DOI: 10.1158/1078-0432.CCR-08-0643. View

Stupp R, Hegi M, Mason W, van den Bent M, Taphoorn M, Janzer R . Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009; 10(5):459-66. DOI: 10.1016/S1470-2045(09)70025-7. View

Weller M, Gorlia T, Cairncross J, van den Bent M, Mason W, Belanger K . Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma. Neurology. 2011; 77(12):1156-64. PMC: 3265044. DOI: 10.1212/WNL.0b013e31822f02e1. View

Eyal S, Yagen B, Sobol E, Altschuler Y, Shmuel M, Bialer M . The activity of antiepileptic drugs as histone deacetylase inhibitors. Epilepsia. 2004; 45(7):737-44. DOI: 10.1111/j.0013-9580.2004.00104.x. View

10.

. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008; 455(7216):1061-8. PMC: 2671642. DOI: 10.1038/nature07385. View

11.

Van Nifterik K, van den Berg J, Slotman B, Lafleur M, Sminia P, Stalpers L . Valproic acid sensitizes human glioma cells for temozolomide and γ-radiation. J Neurooncol. 2011; 107(1):61-7. DOI: 10.1007/s11060-011-0725-z. View

12.

van Breemen M, Wilms E, Vecht C . Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management. Lancet Neurol. 2007; 6(5):421-30. DOI: 10.1016/S1474-4422(07)70103-5. View

13.

Munshi A, Kurland J, Nishikawa T, Tanaka T, Hobbs M, Tucker S . Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity. Clin Cancer Res. 2005; 11(13):4912-22. DOI: 10.1158/1078-0432.CCR-04-2088. View

14.

Scott C, Scarantino C, Urtasun R, Movsas B, Jones C, Simpson J . Validation and predictive power of Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis classes for malignant glioma patients: a report using RTOG 90-06. Int J Radiat Oncol Biol Phys. 1998; 40(1):51-5. DOI: 10.1016/s0360-3016(97)00485-9. View

15.

Tsai H, Wei K, Tsai C, Huang Y, Chen P, Chen S . Effect of valproic acid on the outcome of glioblastoma multiforme. Br J Neurosurg. 2011; 26(3):347-54. DOI: 10.3109/02688697.2011.638996. View

16.

Phiel C, Zhang F, Huang E, Guenther M, Lazar M, Klein P . Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem. 2001; 276(39):36734-41. DOI: 10.1074/jbc.M101287200. View

17.

Mirimanoff R, Gorlia T, Mason W, van den Bent M, Kortmann R, Fisher B . Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. J Clin Oncol. 2006; 24(16):2563-9. DOI: 10.1200/JCO.2005.04.5963. View

18.

Camphausen K, Cerna D, Scott T, Sproull M, Burgan W, Cerra M . Enhancement of in vitro and in vivo tumor cell radiosensitivity by valproic acid. Int J Cancer. 2004; 114(3):380-6. DOI: 10.1002/ijc.20774. View